2003 Claude S. Hudson award address in carbohydrate chemistry. Heparin: Structure and activity

Journal of Medicinal Chemistry

Volumn 46, Issue 13, 2003, Pages 2551-2564

  Linhardt, Robert J ^a  

^a IA United States   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; ANTICOAGULANT AGENT; ANTITHROMBIN III; FIBRIN; FIBROBLAST GROWTH FACTOR; HEPARAN SULFATE; HEPARIN; HEPARIN BINDING PROTEIN; HEPARIN LYASE; LOW MOLECULAR WEIGHT HEPARIN; NATURAL PRODUCT; PROSTAGLANDIN;

ANTICOAGULATION; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOSYNTHESIS; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; COMPLEX FORMATION; CONFERENCE PAPER; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG HALF LIFE; DRUG ISOLATION; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG RESEARCH; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; AWARDS AND PRIZES; CARBOHYDRATE SEQUENCE; HEPARIN; HEPARITIN SULFATE; HISTORY, 20TH CENTURY; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT;

EID: 0038792320     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030176m     Document Type: Conference Paper

References (114)

1. Linhardt, R. J. Heparin: an important drug enters its seventh decade. Chem. Ind. 1991, 2, 45-50.
2. Dahlback, B. Blood coagulation. Lancet 2000, 355, 1627-1632.
3. Roden, L. Highlights in the history of heparin. In Heparin Chemical and Biological Properties, Clinical Applications; Lane, D. A., Lindahl, U., Eds.; CRC Press: Boca Raton, FL, 1989; pp 1-25.
4. Bigelow, W. G. Mysterious Heparin; McGraw-Hill Ryerson Ltd.: Toronto, 1990.
5. Edens, R. E.; Al-Hakim, A.; Weiler, J. M.; Rethwisch, D. G.; Fareed, J.; Linhardt, R. J. Gradient Polyacrylamide Gel Electrophoresis for Determination of the Molecular Weights of Heparin Preparations and Low-Molecular-Weight Heparin Derivatives. J. Pharm. Sci. 1992, 81, 823-827.
6. Ahsan, A.; Jeske, W.; Hoppensteadt, D.; Lormeau, J. C.; Wolf, H.; Fareed, J. Molecular profiling and weight determination of heparins and depolymerized heparins. J. Pharm. Sci. 1995, 84, 724-727.
7. Linhardt, R. J.; Rice, K. G.; Kim, Y. S.; Lohse, D. L.; Wang, H. M.; Loganathan, D. Mapping and quantification of the major oligosaccharide components of heparin. Biochem. J. 1988, 254, 781-787.
8. Loganathan, D.; Wang, H. M.; Mallis, L. M.; Linhardt, R. J. Structural variation in the antithrombin III binding site region and its occurrence in heparin from different sources. Biochemistry 1990, 29, 4362-4368.
9. Pervin, A.; Gallo, C.; Jandik, K. A.; Han, X.-J.; Linhardt, R. J. Preparation and structural characterization of large heparinderived oligosaccharides. Glycobiology 1995, 5, 83-95.
10. Yamada, S.; Sugahara, K. Structure of oligosaccharides isolated from heparan sulfate and heparin and substrate specificities of the degrading enzymes of bacterial origin. Trends Glycosci. Glycotechnol. 1998, 10, 95-123.
11. Linhardt, R. J.; Toida, T. Heparin oligosaccharides: new analogues-development and applications. In Carbohydrates in Drug Design; Witczak, Z. J., Nieforth, K. A., Eds.; Marcel Dekker: New York, 1997; Chapter 7, pp 277-341.
12. Stringer, S. E.; Gallagher, J. T. Heparan sulphate. Int. J. Biochem. Cell Biol. 1997, 29, 709-714.
13. Griffin, C. C.; Linhardt, R. J.; VanGorp, C. L.; et al. Isolation and characterization of heparan sulfate from crude porcine intestinal mucosa peptidoglycan heparin. Carbohydr. Res. 1995, 276, 183-197.
14. Capila, I.; Linhardt, R. J. Heparin-Protein Interactions. Angew. Chem., Int. Ed. 2002, 41, 390-412; Angew. Chem. 2002, 114, 426-450.
15. Capila, I.; Linhardt, R. J. Heparin-Protein Interactions. Angew. Chem., Int. Ed. 2002, 41, 390-412; Angew. Chem. 2002, 114, 426-450.
16. Nader, H. B.; Dietrich, C. P. Natural occurrence and possible biological role of heparin. In Heparin Chemical and Biological Properties, Clinical Applications; Lane, D. A., Lindahl, U., Eds.; CRC Press: Boca Raton, FL, 1989; pp 115-133.
17. Warda, M.; Mao, W.; Toida, T.; Linhardt, R. J. Turkey intestine as a commercial source of heparin? Comparative structural studies of intestinal avian and mammalian glycosaminoglycans. Comp. Biochem. Physiol. B 2003, 134, 189-197.
18. Enerbäck, L. The mast cell system. In Heparin Chemical and Biological Properties, Clinical Applications; Lane, D. A., Lindahl, U., Eds.; CRC Press: Boca Raton, FL, 1989; pp 97-113.
19. Marcum, J. A.; Rosenberg, R. D. Anticoagulantly active heparan sulfate proteoglycan and the vascular endothelium. Semin. Thromb. Hemostasis 1987, 13, 464-474.
20. Rosenberg, R. D.; Shworak, N. W.; Liu, J.; Schwartz, J. J.; Zhang, L. Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J. Clin. Invest. 1997, 100, S67-S75.
21. Linhardt, R. J.; Ampofo, S. A.; Fareed, J.; Hoppensteadt, D.; Mulliken, J. B.; Folkman, J. Isolation and Characterization of Human Heparin. Biochemistry 1992, 31, 12441-12445.
22. Linhardt, R. J.; Gunay, N. S. Production and Chemical Processing of Low Molecular Weight Heparins. Semin. Thromb. Hemostasis 1999, 25, 5-16.
23. Lindahl, U.; Feingold, D. S.; Roden, L. Biosynthesis of heparin. Trends Biochem. Sci. 1986, 11, 221-225.
24. Robinson, H. C.; Horner, A. A.; Höök, M.; Ogren, S.; Lindahl, U. A proteoglycan form of heparin and its degradation to singlechain molecules. J. Biol. Chem. 1978, 253, 6687-6693.
25. Esko, J. D.; Selleck, S. B. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 2002, 71, 435-471.
26. Toida, T.; Yoshida, H.; Toyoda, H.; Koshiishi, I.; Imanari, T.; Hileman, R. E.; Fromm, J. R.; Linhardt, R. J. Structural Differences and the Presence of Unsubstituted Amino Groups in Heparan Sulphates from Different Tissues and Species. Biochem. J. 1997, 322, 499-506.
27. Casu, B. Structure and biological activity of heparin. Adv. Carbohydr. Chem. Biochem. 1985, 43, 51-134.
28. Gallagher, J. T.; Walker A. Molecular distinctions between heparan sulphate and heparin. Biochem. J. 1985, 230, 665-674.
29. Lindahl, U.; Kusche-Gullberg, M.; Kjellén, L. Regulated diversity of heparan sulfate. J. Biol. Chem. 1998, 273, 24979-24982.
30. Pejler, G.; Danielsson, A.; Bjork, I.; Lindahl, U.; Nader, H. B.; Dietrich, C. P. Structure and antithrombin-binding properties of heparin isolated from the clams Anaomalocardia brasiliana and Tivela mactrodies. J. Biol. Chem. 1987, 262, 11413-11421.
31. Shworak, N. W.; Liu, J.; Petros, L. M.; Zhang, L.; Kobayashi, M.; Copeland, N. G.; Jenkins, N. A.; Rosenberg, R. D. Multiple isoforms of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. Isolation, characterization, and expression of human cDNAs and identification of distinct genomic loci. J. Biol. Chem. 1999, 274, 5170-5184.
32. Liu, J.; Shworak, N. W.; Sinay, P.; Schwartz, J. J.; Zhang, L.; Fritze, L. M.; Rosenberg, R. D. Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities. J. Biol. Chem. 1999, 274, 5185-5192.
33. Shukla, D.; Liu, J.; Blaiklock, P.; Shworak, N. W.; Bai, X.; Esko, J. D.; Cohen, G. H.; Eisenberg, R. J.; Rosenberg, R. D.; Spear, P. G. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 1999, 99, 13-22.
34. Liu, J.; Shriver, Z.; Pope, R. M.; Thorp, S. C.; Raska, C. S.; Yoshida, K.; Eisenberg, R. J.; Cohen, G.; Linhardt, R. J.; Sasisekharan, R. Characterization of a Heparan Sulfate Octasaccharide that Binds to Herpes Simplex Viral Type 1 Glycoprotein D. J. Biol. Chem. 2002, 277, 33456-33467.
35. Linhardt, R. J. In Current Protocols in Molecular Biology, Analysis of Glycoconjugates; Varki, A., Ed.; Wiley-Interscience: Boston, MA, 1994; pp 17.13.17-17.13.32.
36. Lohse, D. L.; Linhardt, R. J. Purification and characterization of heparin lyases from Flavobacterium heparinum. J. Biol. Chem. 1992, 267, 24347-24355.
37. Conrad, H. E. Degradation of heparan sulfate by nitrous acid. Methods Mol. Biol. 2001, 171, 347-351.
38. Toida, T.; Huang, Y.; Washio, Y.; Maruyama, T.; Toyoda, H.; Imanari, T.; Linhardt, R. J. Chemical microdetermination of heparin in plasma. Anal. Biochem. 1997, 251 (2), 219-226.
39. Ampofo, S. A.; Wang, H. M.; Linhardt, R. J. Disaccharide Compositional Analysis of Heparin and Heparan Sulfate Using Capillary Zone Electrophoresis. Anal. Biochem. 1991, 199, 249-255.
40. Liu, J.; Desai, U. R.; Han, X.-J.; Toida, T.; Linhardt, R. J. Strategy for the Sequence Analysis of Heparin. Glycobiology 1995, 5, 765-774.
41. Turnbull, J. E.; Hopwood, J. J.; Gallagher, J. T. A strategy for rapid sequencing of heparan sulfate and heparin saccharides. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 2698-2703.
42. Islam, T.; Butler, M.; Sikkander, S, A.; Toida, T.; Linhardt, R, J. Periodate Cleavage of Heparin Occurs Primarily through the Antithrombin Binding Site. Carbohydr. Res. 2002, 337, 2239- 2243.
43. Turnbull, J. E. Integral glycan sequencing of heparan sulfate and heparin saccharides. Methods Mol. Biol. 2001, 171, 129-139.
44. Thanawiroon, C.; Rice, K. G.; Toida, T.; Linhardt, R. J. LC/MS Sequencing of Highly Sulfated Heparin-Derived Oligosaccharides. J. Biol. Chem., submitted in 2003.
45. Farooqui, A. A.; Horrocks, L. A. Heparin-Sepharose Affinity Chromatography. Adv. Chromatogr. 1984, 23, 127-148.
46. Thanawiroon, C.; Mao, C. W.; Linhardt, R. J. Characterization of Polysaccharide Interactions. In Affinity Capillary Electrophoresis in Pharmaceutics and Biopharmaceutics; Neubert, R. H. H., Riittinger, R. H. H., Eds.; Marcel Dekker: New York, 2002; Chapter 11, pp 265-301.
47. Mach, H.; Volkin, D. B.; Burke, C. J.; Middaugh, C. R.; Linhardt, R. J.; Fromm, J.; Loganathan, D,; Mattsson, L. Nature of the Interaction of Heparin with Acidic Fibroblast Growth Factor. Biochemistry 1993, 32, 5480-5489.
48. Salmivirta, M.; Lidholt, K.; Lindahl, U. Heparan sulfate: a piece of information. FASEB J. 1996, 10, 1270-1279.
49. Gallagher, J. T.; Turnbull, J. E.; Lyon, M. Patterns of sulphation in heparan sulphate: polymorphism based on a common structural theme. Int. J. Biochem. 1992, 24, 553-560.
50. Bernfield, M.; Götte, M.; Park, P. W.; Reizes, O.; Fitzgerald, M. L.; Lincecum, J.; Zako, M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 1999, 68, 729-777.
51. Mulloy, B.; Forster, M. J.; Jones, C.; Davies, D. B. N.m.r. and molecular-modelling studies of the solution conformation of heparin. Biochem. J. 1993, 293, 849-858.
52. Casu, B. Heparin structure. Haemostasis 1990, 20, 62-73.
53. Jaques, L. B. Heparin: an old drug with a new paradigm. Science 1979, 206, 528-533.
54. Höök, M.; Bjork, I.; Hopwood, J.; Lindahl, U. Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett. 1976, 66, 90-93.
55. Rosenberg, R. D.; Lam, L. Correlation between structure and function of heparin. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 1218-1222.
56. Lindahl, U.; Backström, G.; Höök, M.; Thunberg, L.; Fransson, L.-A.; Linker, A. Structure of the antithrombin-binding site in heparin. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 3198-3202.
57. Leder, I. G. A novel 3-O sulfatase from human urine acting on methyl-2-deoxy-2-sulfamino-alpha-D-glucopyranoside 3-sulfate. Biochem. Biophys. Res. Commun. 1980, 94, 1183-1189.
58. Lindahl, U.; Backström, G.; Thunberg, L.; Leder, I. G. Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 6551-6555.
59. Casu, B.; Oreste, P.; Torri, G.; Zoppetti, G.; Choay, J.; Lormeau, J.-C.; Petitou, M.; Sinay, P. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Biochem. J. 1981, 197, 599-609.
60. Sinay, P.; Jacquinet, J.-C.; Petitou, M.; Duchaussoy, P.; Lederman, I.; Choay, J.; Torri, G. Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III. Carbohydr. Res. 1984, 132, C5-C9.
61. Atha, D. H.; Lormeau, J.-C.; Petitou, M.; Rosenberg, R. D.; Choay, J. Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. Biochemistry 1987, 26, 6454-6461.
62. Karst, N. A.; Linhardt, R. J. Recent Chemical and Enzymatic Approaches to the Synthesis of Glycosaminoglycan Oligosaccharides. Curr. Med. Chem., in press.
63. Avci, F. Y.; Karst, N. A.; Linhardt, R. J. Synthetic Oligosaccharides as Heparin-Mimetics Displaying Anticoagulant Properties. Curr. Pharm. Des., in press.
64. Sinaÿ, P. Sugars slide into heparin activity. Nature 1999, 398, 377-378.
65. Capila, I.; Hernáiz, M. J.; Mo, Y. D.; Mealy, T. R.; Campos, B.; Dedman, J. R.; Linhardt, R. J.; Seaton, B. A. Annexin V-Heparin Oligosaccharide Complex Suggests Heparan Sulfate-Mediated Assembly on Cell Surfaces. Structure 2001, 9, 57-64.
66. Mousa, S. A.; Fareed, J. Overview: from heparin to low molecular weight heparin: beyond anticoagulation. Curr. Opin. Invest. Drugs 2001, 2, 1077-1080.
67. Langer, R. S.; Linhardt, R. J.; Cooney, C. L.; Fitzgerald, G.; Grant, A. Heparinase derived anticoagulants. U.S. Patent 4,- 396, 762, 1983.
68. Fareed, J.; Jeske, W.; Hoppensteadt, D.; Clarizio, R.; Walenga, J. M. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am. J. Cardiol. 1998, 82, 3L-10L.
69. Linhardt, R. J.; Loganathan, D.; Al-Hakim, A.; Wang, H. M.; Walenga, J. M.; Hoppensteadt, D.; Fareed, J. Oligosaccharide Mapping of Low Molecular Weight Heparins: Structure and Activity Differences. J. Med. Chem. 1990, 33, 1639-1645.
70. Jeske, W. P.; Walenga, J. M. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. Curr. Opin. Invest. Drugs 2002, 3, 1171-1180.
71. Mikhailov, D.; Young, H. C.; Linhardt, R. J.; Mayo, K. H. Heparin Dodecasaccharide Binding to Platelet Factor-4: Introduction of a Partially Folded State and Implications for Heparin Induced Thrombocytopenia. J. Biol. Chem. 1999, 274, 25317-25329.
72. Cardin, A. D.; Weintraub, H. J. R. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989, 9, 21-32.
73. Hileman, R. E.; Fromm, J. R.; Weiler, J. M.; Linhardt, R. J. Glycosaminoglycan-Protein Interaction: Definition of Consensus Sites in Glycosaminoglycan Binding Proteins. BioEssays 1998, 20, 156-167.
74. Caldwell, E. E. O.; Nadkarni, V. D.; Fromm, J. R.; Linhardt, R. J.; Weiler, J. M. Importance of Specific Amino Acids in Protein Binding Sites for Heparin and Heparan Sulfate. Int. J. Biochem. Cell Biol. 1996, 28, 203-216.
75. Fromm, J. R.; Hileman, R. E.; Caldwell, E. E. O.; Weiler, J. M.; Linhardt, R. J. Differences in the Interaction of Heparin with Arginine and Lysine and the Importance of These Basic Amino Acids in the Binding of Heparin to Acidic Fibroblast Growth Factor. Arch. Biochem. Biophys. 1995, 323, 279-287.
76. Fromm, J. R.; Hileman, R. E.; Caldwell, E. E. O.; Weiler, J. M.; Linhardt, R. J. Pattern and Spacing of Basic Amino Acids in Heparin Binding Sites. Arch. Biochem. Biophys. 1997, 343, 92-100.
77. Faham, S. Hileman, R. E.; Fromm, J. R.; Linhardt, R. J.; Rees, D. C. Heparin Structure and Interactions with Basic Fibroblast Growth Factor. Science 1996, 271, 1116-1120.
78. Faham, S.; Linhardt, R. J.; Rees, D. C. Diversity Does Make a Difference: Fibroblast Growth Factor-Heparin Interactions. Curr. Opin. Struct. Biol. 1998, 8, 578-586.
79. Fath, M. A.; Wu, X.; Hileman, R. E.; Linhardt, R. J.; Abraham, W. M.; Kashem, M. A.; Nelson, R. M.; Wright, C. Interaction of Secretory Leukocyte Protease Inhibitor with Heparin Inhibits Proteases Involved in Asthma. J. Biol. Chem. 1998, 273, 13563-13569.
80. Hileman, R. E.; Jennings, R. N.; Linhardt, R. J. Thermodynamic Analysis of Heparin Interaction with a Basic Cyclic Peptide Using Isothermal Titration Calorimetry. Biochemistry 1998, 37, 15231-15237.
81. Bae, J.; Desai, U. R.; Pervin, A.; Caldwell, E. E. O.; Weiler, J. M.; Linhardt, R. J. Interaction of Heparin with Synthetic Antithrombin III Peptide Analogues. Biochem. J. 1994, 301, 121-129.
82. Lander, A. D. Proteoglycans: master regulators of molecular encounter? Matrix Biol. 1998, 17, 465-472.
83. Zhang, F.; Fath, M.; Marks, R.; Linhardt, R. J. A Highly Stable Covalent Conjugated Heparin Biochip for Heparin-Protein Interaction Studies. Anal. Biochem. 2002, 304, 271-273.
84. Kan, M.; Wang, F.; Xu, J.; Crabb, J. W.; Hou, J.; McKeehan, W. L. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 1993, 259, 1918-1921.
85. Schlessinger, J.; Plotnikov, A. N.; Ibrahimi, O. A.; Eliseenkova, A. V.; Yeh, B. K.; Yayon, A.; Linhardt, R. J.; Mohammadi, M. Crystal Structure of a Ternary FGF-FGFR-Heparin Complex Reveals a Dual Role for Heparin in FGFR Binding and Dimerization. Mol. Cell 2000, 6, 743-750.
86. Pellegrini, L.; Burke, D. F.; von Delft, F.; Mulloy, B.; Blundell, T. L. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 2000, 407, 1029-1034.
87. Yeh, B. K.; Plotnikov, A. N.; Eliseenkova, A. V.; Green, D.; Pinnel, J.; Polat, T.; Gritli-Linde, A.; Linhardt, R. J.; Mohammadi, M. Structural Basis for the Therapeutic Activity of Sucrose Octasulfate (SOS). Mol. Cell. Biol. 2002, 22, 7184-7192.
88. Chen, Y.; Maguire, T.; Hileman, R. E.; Fromm, J. R.; Esko, J. D.; Linhardt, R. J.; Marks, R. M. Dengue Virus Infectivity Depends on Envelope Protein Binding To Target Cell Heparan Sulfate. Nat. Med. 1997, 3, 866-871.
89. Marks, R. M.; Lu, H.; Sundaresan, R.; Toida, T.; Suzuki, A.; Imanari, T.; Hernaiz, M. J.; Linhardt, R. J. Probing the Interaction of Dengue Virus Envelope Protein with Heparin: Assessment of Glycosaminoglycan-Derived Inhibitors. J. Med. Chem. 2001, 44, 2178-2187.
90. Warda, M.; Marks, R. M.; Linhardt, R. J. Patents Related to Dengue Virus Infection. Expert Opin. Ther. Pat. 2002, 12, 1127-1144.
91. Rathore, D.; McCutchan, T. F.; Hernaiz, M. J.; LeBrun, L. A.; Lang, S. C.; Linhardt, R. J. Direct Measurement of the Interaction of Glycosaminoglycans and a Heparin Decasaccharide with Malaria Circumsporozoite Protein. Biochemistry 2001, 40, 11518-11524.
92. Dong, J.; Peters-Libeu, C. A.; Weisgraber, K. H.; Segelke, B. W.; Rupp, B.; Capila, I.; Hernaiz, M. J.; LeBrun, L. A.; Linhardt, R. J. Interaction of the N-Terminal Domain of Apolipoprotein E4 with Heparin. Biochemistry 2001, 40, 2826-2834.
93. Bazin, H. G.; Marques, M. A.; Owens, A. P.; Linhardt, R. J.; Krutcher, K. A. Inhibition of Apolipoprotein E-Related Neurotoxicity by Glycosaminoglycans and Their Oligosaccharides. Biochemistry 2002, 41, 8203-8211.
94. Vlodavsky, I.; Friedmann, Y.; Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 2001, 108, 341-347.
95. Langer, R.; Linhardt, R. J.; Hoffberg, S.; Larsen, A. K.; Cooney, C. L.; Tapper, D.; Klein, M. An Enzymatic System for Removing Heparin in Extracorporeal Therapy. Science 1982, 217, 261-263.
96. Sasisekharan, R.; Moses, M. A.; Nugent, M. A.; Cooney, C. L.; Langer, R. Heparinase inhibits neovascularization. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 1524-1528.
97. Borsig, L.; Wong, R.; Feramisco, J.; Nadeau, D. R.; Varki, N. M.; Varki, A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3352-3357.
98. Petitou, M.; van Boeckel, C. A. Chemical synthesis of heparin fragments and analogues. Fortschr. Chem. Org. Naturst. 1992, 60, 143-210.
99. Petitou, M.; Duchaussoy, P.; Driguez, P.-A.; Jaurand, G.; Hérault, J.-P.; Lormeau, J.-C.; van Boeckel, C. A. A.; Herbert, J.-M. First synthetic carbohydrates with the full anticoagulant properties of heparin. Angew. Chem., Int. Ed. 1998, 37, 3009-3014.
100. Westerduin, P.; Basten, J. E. M.; Broekhoven, M. A.; de Kimpe, V.; Kuijpers, W. H. A.; van Boeckel, C. A. A. Synthesis of tailor-made glycoconjugates showing ATIII-mediated inhibition of blood coagulation factors Xa and thrombin. Angew. Chem., Int. Ed. Engl. 1996, 35, 331-333.
101. Koshida, S.; Suda, Y.; Fukui, Y.; Sobel, M.; Ormsby, J.; Kusumoto, S. Synthesis of heparin partial structures and their binding activities to platelets. Bioorg. Med. Chem. Lett. 1999, 9, 3127-3132.
102. Koshida, S.; Suda, Y.; Fukui, Y.; Ormsby, J.; Sobel, M.; Kusumoto, S. Synthesis and biological activity of oligomer-model compounds containing units of a key platelet-binding disaccharide of heparin. Tetrahedron Lett. 1999, 40, 5725-5728.
103. Kovensky, J.; Duchaussoy, P.; Bono, F.; Salmivirta, M.; Sizun, P.; Herbert, J.-M.; Petitou, M.; Sinay, P. A synthetic heparan sulfate pentasaccharide, exclusively containing L-iduronic acid, displays higher affinity for FGF-2 than its D-glucuronic acid-containing isomers. Bioorg. Med. Chem. 1999, 7, 1567-1580.
104. Dreef-Tromp, C. M.; Basten, J. E. M.; Broekhoven, M. A.; van Dinther, T. G.; Petitou, M.; van Boeckel, C. A. A. Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers. Bioorg. Med. Chem. Lett. 1998, 8, 2081-2086.
105. Seeberger, P. H. Solid phase oligosaccharide synthesis. Principles, synthesis, and applications. J. Carbohydr. Chem. 2002, 21, 613-643.
106. Linhardt, R. J.; Kerns, R. J.; Vlahov, I. R. Heparin and Heparin Oligosaccharides: Preparation, Analysis, Applications and Biological Activities. In Biomedical Functions and Biotechnology of Natural and Artificial Polymers; Yalpani, M., Ed.; ATL Press, Science Publishers: Mt. Prospect, IL, 1996; pp 45-62.
107. Bazin, H. G.; Kerns, R. J.; Linhardt, R. J. Regio and Stereoselective Conversion of Δ4-Uronates of L-Ido- and D-Glucopyranosiduronic Acids. Tetrahedron Lett. 1997, 38, 923-926.
108. Giangrande, P. L. Fondaparinux (Arixtra): a new anticoagulant. Int. J. Clin. Pract. 2002, 56, 615-617.
109. Nelson, R. M.; Cecconi, O.; Roberts, W. G.; Aruffo, A.; Linhardt, R. J.; Bevilacqua, M. P. Heparin Oligosaccharides Bind L- and P-Selectin and Inhibit Acute Inflammation. Blood 1993, 82, 3253-3258.
110. Koenig, A.; Norgard-Sumnicht, K.; Linhardt, R. J.; Varki, A. Differential Interactions of Heparin and Heparan Sulfate Glycosaminoglycans with the Selectins. Implications for the Use of Unfractionated and Low Molecular Weight Heparins as Therapeutic Agents. J. Clin. Invest. 1998, 101, 877-889.
111. Wang, H. M.; Toida, T.; Kim, Y. S.; Capila, I.; Hileman, R. E.; Bernfield, M.; Linhardt, R. J. Glycosaminoglycans Can Influence Fibroblast Growth Factor-2 Mitogenicity without Significant Growth Factor Binding. Biochem. Biophys. Res. Commun. 1997, 235, 369-373; Biochem. Biophys. Res. Commun. 1997, 242, 248 (erratum).
112. Wang, H. M.; Toida, T.; Kim, Y. S.; Capila, I.; Hileman, R. E.; Bernfield, M.; Linhardt, R. J. Glycosaminoglycans Can Influence Fibroblast Growth Factor-2 Mitogenicity without Significant Growth Factor Binding. Biochem. Biophys. Res. Commun. 1997, 235, 369-373; Biochem. Biophys. Res. Commun. 1997, 242, 248 (erratum).
113. Downs-Kelly, E.; Jones, M. Z.; Alroy, J.; Cavanagh, K. T.; King, B.; Lucas, R. E.; Baker, J. C.; Kraemer, S. A.; Hopwood, J. J. Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy. J. Mol. Neurosci. 2000, 15, 251-262.
114. Gagneux, P.; Varki, A. Evolutionary considerations in relating oligosaccharide diversity to biological function. Glycobiology 1999, 9, 747-755.